 - Participants with a known mutation in the epidermal growth factor receptor EGFR gene must be documented in the participants chart must have also experienced disease progression or intolerance with an EGFR TKI approved for the treatment of EGFR-mutant NSCLC for example, gefitinib, erlotinib, afatinib. Disease progression or intolerance must be documented 